ReviewExpert review of anticancer therapy2020
The emerging role of antibody-drug conjugates in urothelial carcinoma.
Review in Expert review of anticancer therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 36 citations in OpenAlex.
- Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).British journal of cancer · 2024Trial
- [Advances in intravesical therapy for nonZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.Current opinion in urology · 2026Review
- Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data.World journal of urology · 2026Article
- From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.Frontiers in immunology · 2026Review
- Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.Cancers · 2025Review
- Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Frontiers in immunology · 2025Review
- Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Molecular pharmaceutics · 2024Review
- Article
- The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.Cell death & disease · 2024Review
- Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.Current oncology (Toronto, Ont.) · 2024Review
- Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.Frontiers in pharmacology · 2024Review
- Review
- RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.BMC cancer · 2023Article
- Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Review
- An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.Cancer chemotherapy and pharmacology · 2022Review
- Constructing an immune- and ferroptosis-related lncRNA signature to predict the immune landscape of human bladder cancer.Journal of clinical laboratory analysis · 2022Article
- Nectin-4: a Novel Therapeutic Target for Skin Cancers.Current treatment options in oncology · 2022Review
- Antibody-drug conjugates: beyond current approvals and potential future strategies.Exploration of targeted anti-tumor therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionIn December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial carcinoma. Antibody-drug conjugates represent a new therapeutic modality in urothelial cancer; and beyond nectin-4, agents targeting Trop-2, HER2, and EpCAM are also in clinical development. AREAS COVERED: This review outlines the biologic rationale and the clinical development of novel antibody-drug conjugates for the treatment of urothelial cancer across the spectrum of disease from non-muscle-invasive bladder cancer through treatment-refractory metastatic disease. EXPERT OPINION: The high response rates observed with enfortumab vedotin - both as monotherapy and in combination with checkpoint blockade immunotherapy - suggest this and other antibody-drug conjugates may have efficacy similar to or even exceeding that of traditional cytotoxic chemotherapy. Ongoing clinical development of antibody-drug conjugates in urothelial cancer will address the optimal combination or sequencing strategy with anti-PD-1/L1 immunotherapy and platinum-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.